Cytokinetics reports positive ACACIA-HCM results for aficamten in non-obstructive HCM
The Phase 3 trial hit both primary endpoints, and Cytokinetics plans an FDA supplemental filing in the fourth quarter of 2026.
SEC filing
Latest
3 stories
Friday, August 28
Thursday, August 6
Cytokinetics reports Q2 2026 results, ACACIA-HCM hits both primary endpoints
The company plans a supplemental NDA for aficamten in non-obstructive HCM in the fourth quarter of 2026 after positive Phase 3 topline data.
SEC filing
Wednesday, August 5
Royalty Pharma raises 2026 guidance after 14% Royalty Receipts growth in Q2
The company cited new drug approvals and an expanded pipeline as it lifted its full-year Portfolio Receipts outlook to $3,400 million to $3,500 million.
SEC filing